A Study To Evaluate CKD-701 and Lucentis® in Patients With Neovascular(Wet) Age Related Macular Degeneration
Status:
Completed
Trial end date:
2021-03-17
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, double-blind, active-controlled, parallel group, Phase III
Clinical Trial To Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity of
CKD-701 and Lucentis® in Patients with Neovascular(wet) Age related Macular Degeneration